News
Wegovy, Novo Nordisk's weight loss drug launched in India, check pricing and dosage
Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, improving satiety and reducing cravings for food, eventually inducing weight loss.
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers,
With the launch of Wegovy by Danish pharmaceutical giant Novo Nordisk and US major Eli Lilly’s Mounjaro already in ...
Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...
Diabetes drug Ozempic and weight-loss jab Wegovy may also reduce the risk of dementia, according to a new study. American ...
Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users lose up to 20 per cent body weight. But is it safe? Experts answer.
Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.
Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...
With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.
A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback